Detalles de la búsqueda
1.
Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
Ann Rheum Dis
; 81(6): 789-797, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35318218
2.
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
Ann Rheum Dis
; 78(3): 320-327, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30612115
3.
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
Ann Rheum Dis
; 76(8): 1426-1431, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28473425
4.
The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.
Clin Exp Rheumatol
; 32(6): 869-77, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25327997
5.
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
Arthritis Care Res (Hoboken)
; 74(5): 748-758, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33253491
6.
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
BMJ
; 371: m4328, 2020 12 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33268527
Resultados
1 -
6
de 6
1
Próxima >
>>